Skip to main content

Advertisement

Table 2 Demographic of PLD-treated patients

From: Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations

  BRCA1/2-Aberrant OC (n = 35) Wild-Type OC (n = 76) p-value
No. % No. %  
Age at diagnosis, years      
Median 55   64   <0.001a
Range 39–77   41–82   
Histology      
HGS 34 97.1 70 92.1  
Endometrioid 1 2.9 2 2.6  
Clear Cell 0 0 2 2.6  
Mucinous 0 0 0   0.429b
LGS 0 0 0   
Carcinosarcoma 0 0 2 2.6  
FIGO stage at diagnosis      
I 1 2.9 1 1.4  
II 3 8.6 4 5.6  
III 23 65.7 48 66.7 0.470c
IV 8 22.9 19 26.4  
NA 0 0 4   
Debulking status      
<2 cm 14 42.4 23 31.5 0.282e
≥2 cm 19 57.6 50 68.5  
NA 2   3   
Platinum sensitivity at PLD initiation      
Sensitive 5 15.2 9 12.5  
Resistant 28 84.8 63 87.5 0.761d
NA 2   4   
No. of chemotherapy lines prior to PLD      
≤2 25 71.4 61 80.3 0.429e
>2 10 28.6 15 19.7  
Evaluable for PLD response      
Evaluable 26 74.3 61 80.3 0.644e
Not evaluable 9 15.7 15 19.7  
  1. aWelch Two Sample t-test; bFisher’s exact test, HGS versus non-HGS histology; cFisher’s exact test, early (I-II) versus advanced (III-IV) stage at diagnosis; dFisher’s exact test; eChi-squared test; NA, not available